Quintrio
Home

LABORATORY ANALYTICAL INSTRUMENTS

Quanterix Corporation Common Stock

QTRX

Quanterix Corp is a life sciences company accelerating biomarker breakthroughs from discovery to diagnostics using ultra-sensitive translational research and spatial biology instruments, consumables, and services. The company sells proprietary instruments and related consumables to research laboratories, contract research organizations (CROs), academic institutions, and bio-pharmaceutical companies, and provides contract research services and clinical laboratory testing services, including four Laboratory Developed Tests (LDTs), through its Accelerator Laboratory. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, and SP-X Imaging and Analysis System. Geographically, it operates in North America, EMEA, and the Asia Pacific.

Last trade $2.90
Day change +$0.06 (+2.11%)
Day range $2.76 – $2.96
Volume 309,839
Market cap $135M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$134.84M
Price / earnings
—
Price / book
0.61×
Price / sales
0.91×
EV / sales
0.67×
EV / EBITDA
-1.5×

Profitability

Earnings per share
-$2.34
Return on assets
-37.01%
Return on equity
-50.69%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
3.09×
Quick ratio
2.22×
Cash ratio
0.7×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$56.03M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for QTRX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$34.97M$32.91M$36.42M$43.86M$40.23M$24.48M$30.33M$35.16M
Cost of revenue$21.47M$20.23M$20.85M$23.82M$24.33M$14.48M$15.5M$12.99M
Gross profit$13.5M$12.67M$15.57M$20.04M$15.9M$10M$14.84M$22.17M
Selling, general and administrative$28.45M$27.35M$29.77M$35.14M$38.04M$30.35M$31.17M$28.59M
Research and development$7.37M$7.82M$7.32M$8.8M$8.01M$9.08M$10.04M$8.07M
Total operating expenses$36M$62.11M$55.43M$44.79M$53.23M$47.1M$41.58M$36.94M
Operating income-$22.5M-$49.43M-$39.86M-$24.75M-$37.33M-$37.1M-$26.75M-$14.77M
Interest expense$0$0$0$1.16M$0$0$0$3.49M
Income before taxes-$21.3M-$48.99M-$17.55M-$22.77M-$36M-$30.09M-$23.42M-$11.64M
Income taxes$288K-$54K-$7K$345K-$2.48M-$73K-$2.91M-$8K
Net income-$21.59M-$48.93M-$17.54M-$23.12M-$33.52M-$30.01M-$20.5M-$11.63M
Net income attributable to common shareholders-$21.59M-$48.93M-$17.54M-$23.12M-$33.52M-$30.01M-$20.5M-$11.63M
EBITDA-$15.89M-$16.36M-$15.92M-$17.64M-$24.72M-$27.43M-$24.18M-$13.05M
Basic earnings per share-$0.46-$1.04-$0.37-$0.49-$0.73-$0.77-$0.53-$0.30
Diluted earnings per share-$0.46-$1.04-$0.37-$0.49-$0.73-$0.77-$0.53-$0.30

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Global Alzheimer’s Disease Biomarker Market Poised for Phenomenal Expansion at a Growth Rate of ~9% by 2034 | DelveInsight

The global Alzheimer's disease biomarker market is projected to grow from USD 2.2 billion in 2025 to USD 4.7 billion by 2034, driven by rising disease prevalence, aging populations, and advancements in blood-based biomarkers like phosphorylated tau and amyloid-beta assays. North America leads the market with 41% share, while Asia-Pacific is the fastest-growing region. Recent FDA clearances and expanded laboratory testing availability are accelerating market adoption.

GlobeNewswire Inc.

Global Multiplex Assays Market 2026 Edition - Consumables Dominate Multiplex Assays with 68% Market Share

The global multiplex assays market is projected to grow from US$6.8 billion in 2025 to US$12.4 billion by 2030, at a 12.8% CAGR. North America leads with 34% market share, while Asia Pacific is the fastest-growing region at 15.5% CAGR. Consumables dominate with 68% market share, and protein multiplex assays hold 42%. Growth is driven by precision medicine, companion diagnostics, and laboratory automation.

GlobeNewswire Inc.

Global Blood-Based Biomarkers Market to Witness Upsurge in Growth at a CAGR of ~9% by 2034 | DelveInsight

The global blood-based biomarkers market is projected to grow from USD 8.5 billion in 2025 to USD 18.5 billion by 2034, driven by increasing demand for non-invasive diagnostics, rising chronic disease prevalence, and advances in genomics and liquid biopsy technologies. North America leads with 44% market share, while Asia-Pacific shows fastest growth. Key players include Roche, Abbott, Siemens Healthineers, and Thermo Fisher Scientific.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.